Dynavax Europe was formed following the acquisition of Rhein Biotech GmbH by Dynavax Technologies in April 2006. The company develops, manufactures, licenses-out and markets biopharmaceutical products and technologies. Dynavax Europe has pursued a business model that combines development of proprietary biopharmaceutical products and establishing strategic alliances designed to leverage and add value to its core capabilities in the areas of process, analytical and preclinical development, quality control, quality assurance, manufacturing and technology transfer. Through marketing and sales of recombinant antigens on the diagnostic market, Dynavax Europe leverages the value of the established vaccine production technologies.